# ScoreItem: Vagina e Colo Uterino

**ID:** `019bf31d-2ef0-7f0c-b76b-806c1d6ff1fd`
**FullName:** Vagina e Colo Uterino (Histórico de doenças - Histórico de saúde (Questionar ativamente sobre doenças/sintomas - passado ou atual): - Genitália feminina)

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 16 artigos
- Avg Similarity: 0.540

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7f0c-b76b-806c1d6ff1fd`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7f0c-b76b-806c1d6ff1fd",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Vagina e Colo Uterino (Histórico de doenças - Histórico de saúde (Questionar ativamente sobre doenças/sintomas - passado ou atual): - Genitália feminina)

**30 chunks de 16 artigos (avg similarity: 0.540)**

### Chunk 1/30
**Article:** Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline (2026)
**Journal:** CA: A Cancer Journal for Clinicians
**Section:** abstract | **Similarity:** 0.709

Atualização da diretriz de rastreamento de câncer cervical da American Cancer Society para incluir autocoleta de espécimes vaginais para teste de HPV. Para mulheres de risco médio, recomenda-se iniciar rastreamento aos 25 anos com teste primário de HPV a cada 5 anos até 65 anos. Para teste primário de HPV, espécimes cervicais coletados por clínico são preferidos, mas espécimes vaginais autocoletados são aceitáveis. Quando espécimes vaginais autocoletados são HPV negativos no rastreamento, recomenda-se repetir teste em 3 anos. Para descontinuar rastreamento, recomenda-se que mulheres de risco médio tenham testes primários de HPV negativos ou coteste negativo aos 60 e 65 anos. Esta mudança representa avanço significativo ao aumentar acesso ao rastreamento, particularmente para populações com barreiras ao cuidado tradicional.

---

### Chunk 2/30
**Article:** Cervical Cancer Screening Recommendations: Now and for the Future (2023)
**Journal:** Healthcare (Basel)
**Section:** abstract | **Similarity:** 0.675

Análise comparativa das recomendações globais de rastreamento de câncer cervical das principais organizações de saúde. A WHO recomenda teste de DNA-HPV a cada 5-10 anos a partir dos 30 anos, enquanto a Comissão Europeia sugere teste de HPV a cada 5+ anos para 30-65 anos. Nos EUA, as diretrizes de USPSTF, ACOG, ACS e ASCO endossam teste de HPV a cada 5 anos ou alternativas baseadas em citologia. Identifica infraestrutura limitada, restrições de recursos e lacunas na educação de profissionais como barreiras significativas. Enfatiza que estender intervalos de rastreamento com teste primário de HPV melhora eficiência mantendo segurança. Destaca dual-stain testing para pacientes HPV-positivas e métodos de auto-coleta como tecnologias emergentes para melhorar acesso, particularmente em populações vulneráveis.

---

### Chunk 3/30
**Article:** Primary Human Papillomavirus Testing and Other New Technologies for Cervical Cancer Screening (2023)
**Journal:** Obstet Gynecol
**Section:** abstract | **Similarity:** 0.655

Revisão abrangente sobre a transição do rastreamento citológico tradicional para abordagens baseadas em HPV. Apresenta dados prospectivos robustos que permitem estratificação precisa de risco para identificar pacientes de maior risco de doença, reduzindo procedimentos desnecessários. Discute tecnologias moleculares emergentes como p16/Ki-67 dual stain e testes de metilação de HPV, que demonstram eficácia comparável ao co-teste atual. Analisa o potencial da auto-coleta domiciliar combinada com novas tecnologias para superar barreiras de acesso ao rastreamento, embora identifique desafios de implementação incluindo fluxo de trabalho, limitações de força de trabalho e custos que precisam ser resolvidos para programas mais equitativos.

---

### Chunk 4/30
**Article:** Self-Collected Vaginal Specimens for HPV Testing: Recommendations From the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee (2025)
**Journal:** J Low Genit Tract Dis
**Section:** abstract | **Similarity:** 0.632

Recomendações do consenso de diretrizes sobre o uso de amostras vaginais auto-coletadas para teste de HPV no rastreamento de câncer cervical. Estabelece que testes de HPV em amostras auto-coletadas demonstram desempenho comparável a amostras coletadas por médicos quando ensaios baseados em PCR são utilizados. Recomenda que, embora amostras cervicais coletadas por profissionais sejam preferidas, amostras vaginais auto-coletadas são aceitáveis para rastreamento em indivíduos assintomáticos. Após resultado de HPV negativo por auto-coleta, reteste em 3 anos é recomendado como margem de segurança. Para HPV 16/18 positivo, referência direta para colposcopia é indicada. Aborda barreiras de implementação, reconhecendo que auto-coleta pode expandir acesso ao rastreamento para indivíduos enfrentando obstáculos relacionados ao sistema de saúde, profissionais ou pessoais.

---

### Chunk 5/30
**Article:** A systematic approach to colposcopic examination (2017)
**Journal:** IARC Technical Publications No. 45 - Colposcopy and Treatment of Cervical Precancer
**Section:** abstract | **Similarity:** 0.630

Guia técnico do IARC sobre abordagem sistemática ao exame colposcópico. Estabelece que colposcopia bem-sucedida requer três elementos fundamentais: treinamento adequado, equipamento apropriado e paciente confortável. Competência envolve conhecimento teórico, reconhecimento de imagens, habilidades de manejo de casos e experiência clínica supervisionada de pelo menos 50 casos sob supervisão seguidos de 100 casos não supervisionados revisados por preceptor. Processo sistemático inclui: inserção do espéculo e visualização cervical, avaliação em baixo poder usando solução salina e filtro verde, aplicação de ácido acético seguida por exame em alto poder, documentação de achados incluindo tipo de zona de transformação e escore de Swede, aplicação de iodo para estabelecer limites da zona de transformação. Enfatiza cuidado centrado na paciente: mulher adequadamente orientada é informada, relaxada e confiante, contrastando com pacientes desinformadas que experimentam maior ansiedade e insatisfação. Enfermeira treinada em colposcopia fornece assistência essencial e suporte à paciente durante todo o exame.

---

### Chunk 6/30
**Article:** Gynecologic Pelvic Examination (2024)
**Journal:** StatPearls Publishing
**Section:** abstract | **Similarity:** 0.616

O exame pélvico ginecológico é um componente crítico do cuidado abrangente à saúde da mulher. Envolve inspeção dos genitais externos, exame especular e palpação bimanual para avaliar estruturas reprodutivas internas. Serve para diagnosticar condições incluindo sangramento anormal, corrimento, dor pélvica, infecções e tumores; rastreamento de malignidades; e monitoramento da saúde reprodutiva. A única contraindicação absoluta é a falta de consentimento informado. Diretrizes de organizações como ACOG e ACP variam quanto a exames de rotina em mulheres assintomáticas, com evidências recentes sugerindo benefício limitado para detecção de câncer ovariano, porém o exame pode detectar precocemente cânceres vulvares ou vaginais tratáveis. Complicações incluem desconforto, ansiedade ou trauma mucoso, especialmente em pacientes com vaginite atrófica ou histórico de trauma.

---

### Chunk 7/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.556

oday,therapeuticvaccinesarenotyetavailableforroutineclinicaluse.ProphylacticHPVvaccinationwasintroducedin2007withthegoalofreducingtheincidenceofcervical(pre)malignancies
andtoreduceotherHPVrelatedlesionslikeHSIL.219Thequad-rivalentHPV6/11/16/18andbivalent(16/18)vaccineshowspre-
ventionagainstHPV16-and18-relatedhighgradelesionsof
vulvaandvagina,inwomenwhowereHPV16or18negative
beforevaccination.220Thenonavalentvaccine(HPV6,11,16,18,31,33,45,52and58)doesitslightlybetter.221Proposedreviewdate:2026AcknowledgementsUsefulinputtotheguidelines:Compositionofeditorialboard(see:http://www.iusti.org/regions/Europe/pdf/2013/Editorial_Board.pdf)Listofcontributingorganizations(see:www.iusti.org/regions/Europe/euroguidelines.htm).DataAvailabilityStatementDatasharingisnotapplicabletothisarticleasnonewdatawerecreatedoranalysedinthisstudy.References1GamoudiD,FlewS,CusiniM,BenardonS,PoderA,RadcliffeK.2018Europeanguidelineontheorganizationofaconsultationforsexually
transmittedinfections.JEurAcadDermatolVene

---

### Chunk 8/30
**Article:** Mastologia III (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.549

luto, evitar alarmismo, e definir critérios para exames complementares (ressonância) apenas quando houver fatores de risco adicionais.
- [ ] 4. Atualizar materiais educativos para esclarecer que história familiar, por si só, não contraindica reposição; incorporar achados do Sister Study e WHI.
- [ ] 5. Estabelecer diretriz interna: não indicar reposição hormonal sistêmica em pacientes com histórico de câncer de mama; considerar terapias tópicas para atrofia vaginal após tentativa de métodos não hormonais, com suporte emocional.
- [ ] 6. Criar protocolo de uso criterioso de gestrinona em endometriose e mastalgia refratária, com consentimento informado sobre lacunas de evidência oncológica.
- [ ] 7. Definir critérios de indicação de testosterona por motivos não oncológicos, evitando prescrição para “redução de risco mamário” até que haja validação em guidelines.
- [ ] 8.

---

### Chunk 9/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** discussion | **Similarity:** 0.546

-particlevaccineagainsthigh-gradevulvalandvaginallesions:a
combinedanalysisofthreerandomisedclinicaltrials.Lancet2007;369:1693–1702.221GiulianoAR,JouraEA,GarlandSMetal.Nine-valentHPVvaccineefﬁ-cacyagainstrelateddiseasesanddeﬁnitivetherapy:comparisonwith
historicplacebopopulation.GynecolOncol2019;154:110–117.©2022EuropeanAcademyofDermatologyandVenereologyJEADV2022
VulvalconditionsEuropeanguideline21

---

### Chunk 10/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** discussion | **Similarity:** 0.544

anterSR,CvikoA,YuanL,HechtJL,CrumCP.Vul-varacanthosiswithaltereddifferentiation:aprecursortoverrucouscar-
cinoma?AmJSurgPathol2004;28:638–643.217WatkinsJC,HowittBE,HorowitzNSetal.Differentiatedexophyticvul-varintraepitheliallesionsaregeneticallydistinctfromkeratinizingsqua-
mouscellcarcinomasandcontainmutationsinPIK3CA.ModPathol2017;30:448–458.218VanSetersM,vanBeurdenM,tenKateFetal.Treatmentofvulvarintraepithelialneoplasiawithtopicalimiquimod.NEngJMed2008;358:1465–1473.219PatelC,BrothertonJM,PillsburyAetal.Theimpactof10yearsofhumanpapillomavirus(HPV)vaccinationinAustralia:whatadditional
diseaseburdenwillanonavalentvaccineprevent?EuroSurveill2018;23:1700737.220JouraEA,LeodolterS,Hernandez-AvilaMetal.Efﬁcacyofaquadriva-lentprophylactichumanpapillomovirus(types6,11,16,18)L1virus-
like-particlevaccineagainsthigh-gradevulvalandvaginallesions:a
combinedanalysisofthreerandomisedclinicaltrials.Lancet2007;369:1693–1702.221GiulianoAR,JouraEA,GarlandSMetal.Nine-valentHPVvaccineefﬁ-cac

---

### Chunk 11/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.543

tiation216�DEVIL:Differentiatedexophyticvulvarintraepitheliallesion217ManagementHSILSurgicaltreatmenthasbeentheﬁrstchoiceoftreatment,butrecurrenceratesarehighandthereisanegativeeffecton
qualityoflifeandsexualfunction.Anewtreatmentmodalityis
theapplicationofimiquimodcream,animmuneresponsemod-
iﬁerwithindirectantiviralandantitumourproperties.218(GRADE1B)�Surgicalcoldknifeexcision�LaserCO2therapy�Loopelectrosurgicalexcisionprocedure(LEEP)�Imiquimodcream�Followupwithouttreatment(spontaneousregression)DVIN�SurgicalcoldknifeexcisionFollowupClosefollow-upismandatory,lifelongHSIL�Every6–12months,withannualcervicalsmearDVIN�Dependsonunderlyingdisease,butatleastevery6monthsVaccinationSeveraltypesoftherapeuticHPVvaccineshavebeendevelopedshowingdifferentratesofclinicalsuccess.Today,therapeuticvaccinesarenotyetavailableforroutineclinicaluse.ProphylacticHPVvaccinationwasintroducedin2007withthegoalofreducingtheincidenceofcervical(pre)malignancies
andtoreduceotherHPVrelatedlesi

---

### Chunk 12/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** introduction | **Similarity:** 0.531

rade recommendations and levels of evidence are explained in 
Supplementary Table 1
.

DeLuca et al. 
10.3389/fmed.2023.1106318
Frontiers in 
Medicine
14
frontiersin.org
observed in 3.5 to 7% of women with VLS, while up to 65% of 
vulvar carcinomas arise on a background of VLS (
209
). Hence, early 
detection of premalignant lesions and a lifelong follow-up are 
required (
13
,
 
210
). In a retrospective study, the neoplasia incidence 
rate in 976 women with VLS was 8.1 per 1,000 person-years, and 
the cumulative probability of progression to vulvar cancer escalates 
from 1.2% at 2 years to 36.8% at 25 years (
211
). In another cohort, 
VLS predisposed women under 70 years of age for vulvar SCC, with 
a attributable risk of 98% (
209
). Penile SCC was estimated in 4 to 
13.4% of MGLS cases (
210
,
 
212
,
 
213
). Twelve percent of all penile 
SCC are entirely due to MGLS, whilst it was found that 29.4% of 
them arose in combination with histologically confirmed 
HPV (
214
).

---

### Chunk 13/30
**Article:** Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding (2014)
**Journal:** Cochrane Database of Systematic Reviews
**Section:** abstract | **Similarity:** 0.521

Espessura endometrial ≤4mm tem sensibilidade de 96% e especificidade de 92% para excluir câncer endometrial em mulheres pós-menopáusicas com sangramento

---

### Chunk 14/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.519

1:973–974.211SideriM,JonesRW,WilkinsonEJetal.Squamousvulvarintraepithelialneoplasia:2004modiﬁedterminology,ISSVDvulvaroncologysubcom-
mittee.JReprodMed2005;50:807–810212JouraEA.Epidemiology,diagnosisandtreatmentofvulvarintrepitelialneoplasia.CurrOpinObstetGynecol2002;14:39–43.213JudsonPL,HabermannEB,BaxterNN,DurhamSB,VirnigBA.Trendsintheincidenceofinvasiveandinsituvulvarcarcinoma.ObstetGynecol2006;107:1018–1022.214RomaAA,HartWR.Progressionofsimplex(differentiated)vulvarintraepithelialneoplasisatoinvasivesquamouscellcarcinoma:apro-spectivecasestudyconﬁrmingitsprecursorroleinthepathogenesisofvulvarcancer.IntJGynecolPathol2007;26:248–253.215VandeNieuwenhofHP,vanderAvoortIA,deHulluJA.Reviewofsquamouspremalignantvulvarlesions.CritRevOncolHematol2008;68:131–156.216NascimentoAF,GranterSR,CvikoA,YuanL,HechtJL,CrumCP.Vul-varacanthosiswithaltereddifferentiation:aprecursortoverrucouscar-
cinoma?AmJSurgPathol2004;28:638–643.217WatkinsJC,HowittBE,HorowitzNSetal.Differentiatedexoph

---

### Chunk 15/30
**Article:** International Urogynecology consultation chapter 2 committee 3: the clinical evaluation of pelvic organ prolapse including investigations into associated morbidity/pelvic floor dysfunction (2023)
**Journal:** International Urogynecology Journal
**Section:** results | **Similarity:** 0.513

hersome POPSpearman correlation coeﬃcient between MRD grading compared with examinationOverallAnterior wall170 patients with POP screenedPOP-Q or BWBWrho −0.001; p=0.998rho 0.197; p=0.154Overall POP-Q stage and anterior wall correlated positively and signiﬁcantly with MRD116 excluded because of incomplete examination or MRD informationMRDPOP-Qrho 0.305; p=0.025rho 0.436; p=0.001MRD may provide diﬀerent information than clinical examination, particularly BW staging

2680
 International Urogynecology Journal (2023) 34:2657–2688
Table 9  (continued)
ReferenceStudy designPopulationMethod(s) of clinical assessmentResultsDiscussionLin etal. [122] (same group as Pollock etal.

---

### Chunk 16/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.509

sorganizationofsqua-mousepithelium,cytologicalatypia,highnuclear/cytoplas-micratio,mitoticﬁguresDVINBiopsy:histopathologyisdifﬁcult�Histopathologicalcharacteristics:hyperplasia,hyperkerato-sis,parakeratosis,elongationandanastomosisofreteridges,
basalcellatypia,prominentnucleoli,atypicalmitosisin
basallayer,dyskeratosis,hypermaturationofreteridgesImmunohistochemistry(p16andp53)ishelpfulindifferenti-atingbetweenHSILanddVIN.HSILisHPVdrivenanddVINis
independentofHPV;p16isamarkerforHPVpositivity,soHSILisp16positiveanddVINisp16negative.HSILshowsnor-malp53anddVINshowsmutationsinthep53gene.Therearetwootherprecursorsofvulvarcancer,theyarebothHPVindependent.©2022EuropeanAcademyofDermatologyandVenereologyJEADV2022
VulvalconditionsEuropeanguideline15

�VAAD:Vulvaracanthosiswithaltereddifferentiation216�DEVIL:Differentiatedexophyticvulvarintraepitheliallesion217ManagementHSILSurgicaltreatmenthasbeentheﬁrstchoiceoftreatment,butrecurrenceratesarehighandthereisanegativeeffecton
qualityofl

---

### Chunk 17/30
**Article:** International Urogynecology consultation chapter 2 committee 3: the clinical evaluation of pelvic organ prolapse including investigations into associated morbidity/pelvic floor dysfunction (2023)
**Journal:** International Urogynecology Journal
**Section:** results | **Similarity:** 0.506

opic defecography or MRI defecography, but how this relates to clinical decision-making or more speciﬁcally outcomes, remains unclear.2. In patients where these diagnoses are in question or in patients who present with GI symptoms, it is reasonable to obtain further imaging and testing beyond a routine clinical examination. However, these additional studies can be expensive and uncomfortable to patients, and currently there is no apparent beneﬁt to identifying an underlying condition that would inﬂuence treatment decisions and outcomes. Until a beneﬁt is established, their routine use in asymptomatic women with POP should be discouraged outside of research protocols.Further research Future studies comparing imaging and physiological testing with clinical examination need to compare their results with standardized clinical evaluation in the form of the POP-Q.

---

### Chunk 18/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** discussion | **Similarity:** 0.506

alcancerandothermalignancies.Finally,eveniflesscommon,anearlydiagnosisofcancermaybedelayedbyvaginalsynechiaeandhematocolposduetovaginal
occlusion(
80

82
).THEBURDENOFVVA/GSMONWOMEN’S
SEXUALFUNCTIONANDQUALITYOF
LIFE(QOL)
Inthelastdecade,manyinternationalsurveysattemptedto
clarifytheimpactofVVA/GSMonsexualfunctionandQoL
(Table2)indicatingthataproactiveapproachtoconversationsaboutvulvovaginaldiscomfortwouldimprovediagnosisandtreatment(
22
).Eventhoughtheproportionofwomenwhoaresexuallyactivedecreaseswithadvancingage,thevalueofdiscussionsaboutsexualhealthisstillhighinelderlywomenwhoareinpartnership(
83
).InthesurveyofMidlifeDevelopmentintheUnitedStates(MIDUSII)womenwhoweremarried
orcohabitatinghadapproximately8timeshigheroddsof
beingsexuallyactive,withmorethan30%ofwomenover
65yearsreportingsexualactivityatleastonceaweek(
84
).Sexualsatisfactionishighlydependentonmanypsychosocial
aspectsrelatedtowell-being(
85
).Inaddition,dimensionsofsexualresponsearepartofthedominoeﬀectofmenopausal

---

### Chunk 19/30
**Article:** International Urogynecology consultation chapter 2 committee 3: the clinical evaluation of pelvic organ prolapse including investigations into associated morbidity/pelvic floor dysfunction (2023)
**Journal:** International Urogynecology Journal
**Section:** results | **Similarity:** 0.504

fecography incorrectly performedPhysical examination, POP-QNo signiﬁcant relationship was found between defecatory symptoms and presence of posterior vaginal wall prolapse on examination (p=0.33), rectocele (n=0.19), or enterocele (n=0.99) on defecographyClinical examination may overestimate posterior vaginal wall prolapse and underestimate enteroceleDDIFluoroscopic defecog-raphy with vagina also opaciﬁedClinical examination diagnosis of a rectocele compared with defecographySensitivity 1.0, 95% CI 0.82 to 1Speciﬁcity 0.23 95% CI −0.11 to 0.38Clinical examination diagnosis of enterocele compared with defecographySensitivity 0.07, 95% CI 0.002 to 0.32Speciﬁcity 0.95, 95% CI 0.85 to 0.99No correlation of bowel symptoms with posterior wall prolapse on examination or rectocele or enterocele on defecography

2678
 International Urogynecology Journal (2023) 34:2657–2688
Table 9  (continued)
ReferenceStudy designPopulationMethod(s) of clinical assessmentResultsDiscussionKim etal.

---

### Chunk 20/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** discussion | **Similarity:** 0.500

owdiscussionandreviewofhistologyresults.PhysicalexaminationofthepatientInformedconsentisapre-requisiteforallexaminations,investi-gationsandtreatments.Consentisparticularlyimportantforintimateexaminationsoftheanogenitalarea.Achaperone
shouldbeofferedinallcasesandthisshouldbedocumented
clearlyinthepatientrecords.Theproposedexaminationshould
beadequatelyexplainedtopatientsbeforetheyundress.All
attemptsshouldbemadetomaintainpatients’dignity,provid-
ingprivacytodressandundress,andkeepingthemcoveredas
muchaspossible.Appropriatefacilitiesandequipmentforinvestigationsshouldbeavailablepriortocommencingtheexamination.Theroomshouldbewelllit,privateandsound-
proofed,withasuitableexaminationcouchofadjustable
height.1DermatosesandSTIsmayco-existorawomanwithapre-existingdermatosismaycontractanSTI.Screeningforsexually
transmittedinfections(STI)shouldbeconsideredinallpatients,
dependingonsymptomsandriskfactors.Ifthepatientpresentswithvulvalitch,particularlywithincreaseddischarge,vulvovagi-nalcandidia

---

### Chunk 21/30
**Article:** Transvaginal ultrasound endometrial thickness measurement for detecting endometrial cancer in postmenopausal women: a systematic review and meta-analysis (2007)
**Journal:** Lancet Oncology
**Section:** abstract | **Similarity:** 0.499

Meta-análise mostrando que cutoff de 5mm tem melhor relação sensibilidade-especificidade para detecção de câncer endometrial

---

### Chunk 22/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.499

alLesion(SIL)ofthe
vulvaorvulvalLSIL.�High-gradeSILofthevulvaorvulvalHSIL�Vulvalintraepithelialneoplasia,differentiatedtype208AetiologyUsingthelatestISSVDterminology,therearetwopremalignant
vulvallesions,whichcanleadtoasquamouscellcarcinomaof
thevulva,namelyHSILandDVIN.Thesearecompletelydiffer-
ententitieswithrespecttoaetiology,malignantpotentialand
treatment.HSILiscausedbyapersistentinfectionwithhighriskHumanPapillomaVirus(HPV).TheincidenceofHSILisapproximately5per100000womenperyearandisincreas-
ing,212withthehighestpeakbetween35and49years.213Area-sonfortheincreasedincidencemaybetheincreaseofanogenital
HPVinfectionsand/orabetterdiagnosisbythemoreliberaluse
ofvulvalbiopsy.Riskfactorsaresmokingandanimmuno-com-
promisedstate.DVINisassociatedwithLSandLPandhasnorelationwithHPV.DVINoccursmainlyinelderlywomen,andcompriseslessthan5%ofVINlesions.ThemalignantpotentialofDVINis
higherthanthatofHSIL.214,215TheaetiologyofDVINisnotclear.SymptomsandsignsHSILDVINSymptomsItching,burning,irritationP

---

### Chunk 23/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.497

8.doi:10.1097/GME.000000000000112177.SadovskyR,BassonR,KrychmanM,MoralesAM,SchoverL,WangR,etal.Cancerandsexualproblems.JSexMed.(2010)7:34973.doi:10.1111/j.1743-6109.2009.01620.x78.NappiRE,CucinellaL,MartiniE,RossiM,TiraniniL,MartellaS,etal.Sexualityinprematureovarianinsuﬃciency.Climacteric.(2019)22:28995.doi:10.1080/13697137.2019.157535679.DoumouchtsisSK,ChrysanthopoulouEL.Urogenitalconsequencesinageingwomen.BestPractResClinObstetGynaecol.(2013)27:699714.doi:10.1016/j.bpobgyn.2013.03.007
FrontiersinEndocrinology|www.frontiersin.org9August2019|Volume10|Article561

Nappietal.VaginalHealthandAging
80.BoltonPJ,Selo-OjemeDO.Endometrialadenocarcinoma:anunusualpresentationwithacuteurinaryretentionsecondarytohaematocolpos.JObstetGynaecol.(1999)19:5534.doi:10.1080/0144361996450881.SegalS,HarvieHS,SiegelmanE,AryaLA.Severeatrophicvaginitiscausingvaginalsynechiaeandhematocolposatmenopause.Menopause.(2011)18:3335.doi:10.1097/gme.0b013e3181f3285a82.StilesM,RedmerJ,PaddockE,SchragerS.Gyne

---

### Chunk 24/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.497

74
).Notwithstandingtheseﬁndings,HCPsmayposeverysimplequestionstofacilitateanopenconversationonurogenital
healthandtorecordthevarietyofvaginal,vulvarandurinarysymptoms.Visualvaginal,vulvarandpelvicassessmentbyHCPs
isausefulmeasurefordiagnosingVVA/GSMandassessing
responsetotreatment.Moreover,itmayhelpHCPstoidentify
womenatriskofvaginaldrynessanddyspareunia,andallow
themtoproactivelyengageinconversationsaboutsexualhealth(
75
).Figure1reportsaverysimplecheck-listtodiagnoseVVA/GSMinroutineclinicalpractice.WomenwithbreastcancerandothergynecologicalmalignanciesareatveryhighriskofVVAandassociated
symptoms.Indeed,endocrinechemotherapy,surgeryand/or
FrontiersinEndocrinology|www.frontiersin.org4August2019|Volume10|Article561

Nappietal.VaginalHealthandAging
FIGURE1|Averysimplecheck-listtodiagnoseVVA/GSMinroutineclinicalpractice.

---

### Chunk 25/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** results | **Similarity:** 0.494

of Vaginal Aging (DIVA) Questionnaire 
[27]
 was performed, which was translated into
the local language for better understanding.
Results
Table 
1
 depicts the distribution of females according to age. A majority (34%) belong to the age group of 56-
60 years, whereas only 6% were of the age group 71-75 years.
2024 Ulhe et al. Cureus 16(2): e54802. DOI 10.7759/cureus.54802
4
 of 
19

Age group
Frequency
Percentage
45-50
11
11
51-55
14
14
56-60
34
34
61-65
22
22
66-70
13
13
71-75
6
6
Total
100
100
TABLE
 1: 
Distribution of females according to age
Among the total females that participated in the study, the majority (36%) of them had their
last menstruation before 5-6 years. About 12% of them had their last menstruation 1-2 years ago, while 27%
had their last menstruation 3-4 years back. About 25% of females reported they had their last menstruation
in more than six years which is depicted in Table 
2
.

---

### Chunk 26/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** introduction | **Similarity:** 0.493

agnosisand
inappropriatetreatmentsmayhaveanegativeprognostic
impact.Vulvalintraepithelialneoplasia(VIN)IntroductionVINisachronicvulvalskindisordercharacterizedbydysplastic
changesofthesquamousepithelium.Itisapremalignantlesion,
althoughspontaneousregressionhasbeenreported.206Inthelast100years,premalignantlesionsofthevulvahavebeen
described,buttherealwayswasadebateabouttheclinicaland
pathologicalcharacteristicsoftheselesions.Theterminologyhas
changedseveraltimessincetheﬁrstdescriptionin1922:‘dysker-
atoseerythroplasiformedelamuqueusevulvaire’.207TheInter-nationalSocietyfortheStudyofVulvovaginalDisease(ISSVD)hadbeenleadingintheprocessofchoosingnewterminologyfor
premalignantvulvallesions.Thelastversionoftheterminology
wasacceptedbytheISSVDin2015(Table1):�Low-gradeSquamousIntraepithelialLesion(SIL)ofthe
vulvaorvulvalLSIL.�High-gradeSILofthevulvaorvulvalHSIL�Vulvalintraepithelialneoplasia,differentiatedtype208AetiologyUsingthelatestISSVDterminology,therearetwopremalignant
vulval

---

### Chunk 27/30
**Article:** ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding (2018)
**Journal:** Obstetrics & Gynecology
**Section:** abstract | **Similarity:** 0.493

Guideline oficial recomendando USG transvaginal como primeiro exame em sangramento pós-menopausa, com cutoff de 4-5mm para biópsia

---

### Chunk 28/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.487

haviouralcognitivetherapy.205Shortandlong-term
Table1EvolutionoftheInternationalSocietyfortheStudyofVulvovaginalDiseaseterminologyFriedrich(1976)209Wilkinsonetal.(1986)210Siderietal.(2004)211Bornsteinetal.(2016)208VulvalatypiaVIN1FlatcondylomaorHPVeffectLSILA.withoutdystrophyVin2cxVIN,usualtypeHSILB.withdystrophySquamouscarcinomainsituVIN3VINusualtypeHSILDifferentiatedVINVINdifferentiatedtypeDVIN,differentiated-typeVIN©2022EuropeanAcademyofDermatologyandVenereologyJEADV2022
14vanderMeijdenetal.

---

### Chunk 29/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.486

oexistentintraepithelialneoplasia/squamouscellcarci-
noma(SCC)issuspected.Directimmunoﬂuorescence
shouldbeperformedifanimmunobullousdiseaseiscon-sideredinthedifferentialdiagnosis.Only25%areclassiconbiopsyandclinico-pathologicalcorrelationis
important.�Thyroidandotherautoimmunediseaseisonlyrarelyasso-
ciatedwithvulvalLP.Investigationforautoimmunedisease
isindicatedifthereisclinicalsuspicionofabnormality.99�Skinswab:toexcludesecondaryinfection,especiallyof
excoriatedlesions.�Patchtesting:ifmedicamentcontactallergysuspected.WhilstalinkwithhepatitisCandsometimesBhasbeennotedinsome(especiallyMediterranean)countries,aUKstudyof100womenwithvulvalmucosalLPfoundnoevidenceofincreasedincidenceandconcludedthatroutinescreeningis
unnecessary.100Neverthelessscreeningmaystillbeprudentinpopulationswithahighprevalenceofviralhepatitis.Complications�Scarring,includingvaginalsynechiae,particularlyseenin
erosivedisease�DevelopmentofSCC.Intheonlyavailableprospective
study,whichcomprisedof114patien

---

### Chunk 30/30
**Article:** Mastologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.481

dos sintomas gerais a investigar em consulta, como dor mamária e TPM intensa, que podem indicar predominância estrogênica.

## Objetivo:
Não há achados de exame físico de um paciente específico. A abordagem objetiva descrita inclui:
- Avaliação da composição corporal por bioimpedância ou densitometria de corpo total, identificando condições como sarcopenia em mulheres com peso normal.
- Solicitação de exames laboratoriais para avaliar marcadores inflamatórios e verificar se a paciente está metabolicamente doente ou em risco.

## Diagnóstico Primário:
- Avaliação: Discussão educacional sobre estratificação de risco para câncer de mama. 90% dos casos relacionam-se ao estilo de vida e 10% a fatores genéticos conhecidos. Mutações de alta penetrância (ex.: BRCA1, BRCA2, TP53) aumentam significativamente o risco, porém são raras. Epigenética e estilo de vida são cruciais e modificáveis.

---

